[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"catecholaminergic-polymorphic-ventricular-tachycardia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:catecholaminergic-polymorphic-ventricular-tachycardia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,87,121,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100604328","phase-1-a-study-of-sgt-501-gene-therapy-in-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt-100604328",false,"NCT07148089","A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)","A Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia","ARTEMIS","Inclusion Criteria:\n\nType of Participant and Disease Characteristics:\n\n* Clinical diagnosis of CPVT, based on documented history of polymorphic or bidirectional non-sustained ventricular tachycardia with exercise or ventricular ectopy in a pattern consistent with CPVT on EST.\n* Central Screening laboratory determination of a RYR2 variant that is pathogenic or likely pathogenic for CPVT.\n* Documented history of life-threatening ventricular arrhythmic event defined as: survived sudden cardiac arrest, sudden cardiac arrest with appropriate implantable cardioverter defibrillator (ICD) shock, arrhythmic syncope, or sustained ventricular tachycardia (30 seconds or more) with or without ICD shock.\n* On stable dose (defined as no change in dose by more than 50% for at least 1 month prior to Screening) of standard-of-care therapy defined as a beta-blocker and\u002For flecainide.\n* Documented prior history of EST demonstrating a ventricular arrythmia score (VAS) score of ≥ 2.\n* For the first 2 participants in each cohort only: a properly functioning ICD device in place. Following review of data from Cohorts 1 and 2, the Data Safety and Monitoring Board (DSMB) will determine if this criterion is required for participants in Cohort 3.\n* Must be up to date with meningococcal vaccination per national guidelines or willing to receive meningococcal vaccine to achieve this.\n* Other inclusion criteria to be applied as per protocol.\n\nExclusion Criteria:\n\n* Abnormal liver function: gamma-glutamyl transferase (GGT) \\> 1.5 × upper limit of normal \\[ULN\\] or total bilirubin \\> ULN).\n* Abnormal renal function defined by estimated glomerular filtration rate \\\u003C 60 milliliter \u002Fminute (mL\u002Fmin)\u002F1.73-square meter (m\\^2) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula.\n* Clinically significant abnormalities of coagulation including international normalized ratio or activated partial thromboplastin time \\> 1.2 × ULN or platelets \\\u003C 150,000 cells\u002Fcubic millimeter (mm\\^3).\n* Potential concomitant cardiomyopathy or inherited arrhythmia as evidenced by pathogenic or likely pathogenic mutation other than RYR2 obtained on cardiac panel during Screening.\n* Current or prior treatment with an approved or investigational gene transfer drug.\n* Exposure to another investigational drug within 90 days prior to Screening or 5 half-lives since last administration, whichever is longer.\n* Contraindication or unwillingness to receive required immunosuppression regimen.\n* Body mass index ≥ 30 kilograms per square meter (kg\u002Fm\\^2).\n* Other exclusion criteria to be applied as per protocol.","ALL","7 Years",{"count":20,"type":21},18,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety data in adult participants. Cohort 1 and Cohort 2 (optional for dose exploration) will include participants ≥ 18 years of age. Cohort 3 will include participants ≥ 7 to \\\u003C 18 years of age and will be initiated following data and safety monitoring board (DSMB) recommendations. Participants will be monitored for 5 years post-administration of SGT-501 including the active treatment period (1 year) and long-term follow-up (LTFU) (4 years) period.",[27],"Catecholaminergic Polymorphic Ventricular Tachycardia",[29,30,31,32,33,34],"Catecholaminergic polymorphic ventricular tachycardia (CPVT)","SGT-501","Ryanodine Receptor 2 (RYR2)","adeno-associated virus serotype 8 (AAV8)","Cardiac","Gene Therapy","RECRUITING","2026-06-01",{"date":38,"type":39},"2026-06-02","ACTUAL",{"date":41,"type":39},"2026-02-23",{"date":43,"type":21},"2031-05",{"name":45,"class":46},"Solid Biosciences Inc.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":73,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055","NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)",{"count":55,"type":21},1211,"6 Months","OBSERVATIONAL","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[60,61,62,63,64,65,66,67,68,69,70,71,27,72],"Cardiomyopathy, Hypertrophic","Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Arrhythmogenic Right Ventricular Dysplasia","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Long QT Syndrome","Short Qt Syndrome","Brugada Syndrome","Sudden Cardiac Death",[74,75],"hereditary cardiovascular diseases","whole genome sequencing","2026-05-04",{"date":78,"type":39},"2026-05-08",{"date":80,"type":39},"2025-04-30",{"date":82,"type":21},"2026-08-31",{"name":84,"class":85},"Hospital do Coracao","OTHER",27,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100566724","phase-2-a-phase-2-study-of-crd-4730-in-cpvt-100566724","NCT06658899","A Phase 2 Study of CRD-4730 in CPVT","A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia","CPVT","Inclusion Criteria:\n\nEach participant must meet all the following criteria to be enrolled in this study:\n\n1. The participant is male or female, ≥18 years of age and of legal adult age in accordance with local requirements.\n2. The participant has a confirmed CPVT diagnosis, based on genetic screening for a pathogenic ryanodine receptor (RYR2) mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the Investigator and documented in the study source records.\n3. The participant can perform an EST during which frequent premature ventricular contractions (PVCs; ≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the Investigator.\n4. The participant has been on a stable dose of at least 1 antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks prior to Screening, unless the participant has been unable to tolerate antiarrhythmic therapy previously.\n5. Adheres to all contraceptive criteria.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded from the study:\n\n1. The participant has clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.\n2. The participant has a clinically significant abnormal ECG not explained by the diagnosis of CPVT at Screening or clinically significant abnormal intervals, such as prolonged QT.\n3. The participant has a history of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of Screening.\n4. The participant undergoes implantable cardioverter-defibrillator (ICD) implantation or has sympathetic nerve denervation within 3 months of Screening.\n5. The participant has an anticipated change in exercise regimen or new exercise program during the course of the study.\n6. The participant has a history of malignancy within the past 5 years at Screening, with the exception of successfully treated basal cell carcinoma or nonmetastatic squamous cell carcinoma of the skin or cervical carcinoma in situ. Prior exposure to chest radiation for any malignancy is exclusionary.\n7. The participant has abnormal blood pressure, defined as supine symptomatic hypotension, systolic blood pressure \\>150 mm Hg or diastolic blood pressure \\>90 mm Hg, or symptomatic bradycardia or a heart rate \\>100 bpm at Screening and\u002For on Day 1. Blood pressure and pulse should be measured after the participant has been in the seated position after 5 minutes of rest.\n8. The participant has hepatic impairment defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × (upper limit of normal \\[ULN\\]) and\u002For total bilirubin \\>1.5 × ULN at Screening (unless secondary to confirmed Gilbert syndrome).\n9. The participant has acute or chronic hepatitis B (HBV; defined as hepatitis B surface antigen \\[HBsAg\\] reactive), acute or chronic hepatitis C virus (HCV; defined as detection of HCV antibody and RNA \\[qualitative\\]), or human immunodeficiency virus (HIV) infection.\n10. The female participant is pregnant, lactating\u002Fbreastfeeding, or has plans to become pregnant during the study or within 3 months following the last study drug administration.\n11. The participant has taken any antiarrhythmic drug in addition to their stable, chronic regimen unless it has been at least 5 half-lives since administration at the time of Screening.","18 Years","99 Years",{"count":98,"type":21},12,[100],"PHASE2","This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.",[27],[104,93,105,106,107,108,27,109,110],"CaMKII","Ventricular Tachycardia","CRD-4730","Cardiovascular","Arrhythmia","CaM kinase II","Calmodulin-dependent protein kinase II","2026-02-25",{"date":113,"type":39},"2026-02-27",{"date":115,"type":39},"2025-12-01",{"date":117,"type":21},"2027-04",{"name":119,"class":46},"Cardurion Pharmaceuticals, Inc.",9,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":95,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":143},"100613173","phase-2-safety-tolerability-and-exploratory-efficacy-of-agp100-in-patients-with-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt-100613173","NCT07263139","Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)","A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (PACE-CPVT)","Inclusion Criteria:\n\n1. Signed informed consent prior to any study-related procedures\n2. Male or female, aged between 18 and 75 years (inclusive)\n3. Clinical diagnosis of CPVT based on proven RYR2 mutation AND reproducible premature ventricular contraction with exercise or polymorphic or bidirectional ventricular tachycardia with exercise\n4. Able and willing to undergo exercise testing (bicycle test) AND exhibits exercise-induced ventricular ectopic beats at Screening (at least 1 point on the VA scale)\n5. On stable, maximum tolerated, dose of non-selective β-blocker for at least 4 weeks before Visit 1. The dosage and choice of β-blocker are to be determined by the patients' physician(s) before entry into the study and must remain unchanged throughout the conduct of the study. Participants taking a stable dose of flecainide for at least 4 weeks, in addition to β-blocker, are also eligible.\n6. Clinical laboratory evaluations including clinical chemistry, haematology, urinalysis, thyroid function (including thyroid stimulating hormone, triiodothyronine, thyroxine, and free T4) and coagulation testing (activated partial thromboplastin time, and international normalized ratio) within the reference range, unless deemed not clinically significant by the Investigator\n7. Willing to refrain from strenuous or new exercise for 24 hours before each study visit\n8. Women of childbearing potential (WOCBP) agree to implement accepted and highly effective means of contraception from study entry until at least 33 days after study drug discontinuation (as per the Clinical Trials Facilitation and Coordination Group guidelines).\n\nThe main exclusion criteria are:\n\n1. Diagnosis of structural heart disease, including coronary artery disease or heart failure with reduced ejection fraction (left ventricular ejection fraction \\\u003C45%)\n2. Participants who have had arrhythmias causing hemodynamic instability at previous exercise tests (performed while on the current standard of care treatment)\n3. Participants having a sustained VT (VA score of 5) during the exercise tests performed as part of the screening activities\n4. Participation in another clinical study with an investigational product or device within 60 days of 5 half-lives prior to Baseline (whichever is longer)\n5. Medical history of severe anaphylactic reactions to any component(s) of the IMP\n6. Sensitivity to any of the study treatments, or components thereof, or any drug or other allergy that, in the opinion of the Investigator precludes participation in the study\n7. Hypersensitivity or contraindication to PDE2 inhibitor drugs\n8. Use of PDE3, PDE4, or PDE5 inhibitor drugs.\n9. Participants taking any antiarrhythmic drug(s) except flecainide and non-selective β-blockers\n10. Significant hypertension (defined as systolic blood pressure of \\>160 mmHg and\u002For diastolic blood pressure of \\>95 mmHg). If the blood pressure results are out of range at Screening, the measurements can be repeated on the same day more than once, or at another convenient visit\n11. Prolonged PR and\u002For QTc interval at Screening, defined as PR \\>240 ms or QTc \\>480 ms","75 Years",{"count":130,"type":21},10,[100],"This trial is conducted in patients with an inherited heart rhythm disorder called catecholaminergic polymorphic ventricular tachycardia (CPVT). This condition causes the heart to beat dangerously fast during situations of physical or emotional stress. CPVT is a serious condition that can limit the length and quality of patients' lives. Current treatment does not always prevent the abnormal heart rhythms that can occur as part of CPVT during strenuous exercise or stress, so new and improved medications are needed.\n\nThe main questions that the trial will answer are:\n\n* How safe and tolerable is the drug AGP100; i.e, what medical problems do patients experience when taking the drug?\n* Does the drug help CPVT patients to maintain a normal heart rhythm while they are exercising?\n* How does the drug affect the levels of key heart cell signalling molecules?\n\nPatients with a diagnosis of CPVT who are aged between 18 and 75 and experience abnormal heart rhythms during exercise, despite taking a stable dose of the medication(s) prescribed by their doctor for their CPVT can take part in this trial. Participants should have normal kidney and liver function and not have high blood pressure or a diagnosis of structural heart disease. Women who are pregnant or breastfeeding cannot take part in the study. Participants who may become pregnant (and their partners) need to use highly effective methods of contraception during the study and for 90 days after the study ends.\n\nParticipants will take part in the study for ten weeks. During this time, participants will be asked to take three different doses of the the drug (AGP100), as well as their normal heart medication. The drug is an oral capsule and each different dose will be taken once a day for 13 days. The study starts with participants taking a low dose for 2 weeks, then a medium dose and then a high dose. At each dose, participants will undergo a clinical examination, report any potential side effects and the treating doctor will investigate the safety, tolerability and side effects of AGP100. In total, participants will take AGP100 once a day for about six weeks. The last four weeks of the study will be a follow-up period where participants will not take AGP100.\n\nDuring the study, participants will need to visit the hospital six times. The visits will be three outpatient appointments and three overnight stays.",[27],"2025-12-19",{"date":136,"type":39},"2025-12-26",{"date":138,"type":21},"2026-01-02",{"date":140,"type":21},"2027-06-30",{"name":142,"class":46},"Agiana Pharmaceuticals",1,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":17,"minAge":95,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":57,"phases":4,"briefSummary":156,"conditions":157,"keywords":165,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":143},"100479320","clinical-cohort-study---trust-100479320","NCT05521451","Clinical Cohort Study - TRUST","Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg","TRUST","Inclusion Criteria:\n\n* Cardiac arrhythmia, including congenital cardiac arrhythmia diagnosed at baseline or high risk for cardiac arrhythmia\n* Age ≥ 18 years\n* Written informed consent\n* Ability to provide written informed consent in accordance with Good Clinical Practice and local legislation\n\nExclusion Criteria:\n\n* Insufficient knowledge of the German language to understand study documents and interview without translation\n* Physical or psychological incapability to cooperate in the investigation",true,{"count":154,"type":21},5000,"10 Years","The \"Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg\" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.",[158,159,160,105,161,63,69,71,162,27,163,164],"Arrhythmias, Cardiac","Atrial Fibrillation","Atrial Flutter","Atrial Tachycardia","Supraventricular Tachycardia","Torsades De Pointes","Atrial Cardiomyopathy",[166,167,168,169,170,171,164],"Catheter Ablation","Biomarkers","Cardiac Arrhythmia","eHealth","Digital Cardiology","Echocardiography","2025-03-25",{"date":174,"type":39},"2025-03-30",{"date":176,"type":39},"2021-03-17",{"date":178,"type":21},"2031-12-31",{"name":180,"class":85},"Universitätsklinikum Hamburg-Eppendorf"]